Skip to main content

IL-17

      RT @RichardPAConway: Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi sh

      Richard Conway RichardPAConway

      3 years 11 months ago
      Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
      RT @RichardPAConway: Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More

      Richard Conway RichardPAConway

      3 years 11 months ago
      Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
      RT @DrMiniDey: Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondyl

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression. #Abs0909 #ACR21 @RheumNow https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh
      RT @KDAO2011: ⁦@JointMD⁩ shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. ⁦@RheumNowâ

      TheDaoIndex KDAO2011

      3 years 11 months ago
      ⁦@JointMD⁩ shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. ⁦@RheumNow⁩ #acr21 https://t.co/mVw05iFPhF
      Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
      ×